PMID- 34414962
OWN - NLM
STAT- MEDLINE
DCOM- 20210831
LR  - 20230103
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 100
IP  - 33
DP  - 2021 Aug 20
TI  - Efficacy and tolerability of doxazosin gastro-intestinal therapeutic system 
      versus tamsulosin in patients with lower urinary tract symptoms associated with 
      benign prostatic hyperplasia: A systematic review and meta-analysis.
PG  - e26955
LID - 10.1097/MD.0000000000026955 [doi]
LID - e26955
AB  - BACKGROUND: Alpha1-adrenoceptor antagonists (alpha1-blockers) are first-line drugs 
      for the treatment of lower urinary tract symptoms associated with benign prostate 
      hyperplasia (BPH). Doxazosin gastrointestinal therapeutic system (GITS) and 
      tamsulosin belong to the 2 most frequently prescribed alpha1-blockers. This 
      systematic review and meta-analysis was performed to compare the efficacy and 
      tolerability of these 2 alpha1-blockers. METHODS: A systematic review of published 
      randomized controlled trials in English or Chinese language was performed using 
      the PubMed, EMBASE, Cochrane Library, CNKI, Wanfang, and Vip databases. After 
      data extraction and quality assessment, the meta-analysis was performed to 
      compare clinical parameters (International Prostate Symptom Score [IPSS] total 
      [IPSS-T], storage [IPSS-S], voiding [IPSS-V], maximum urine flow [Qmax], and 
      postvoid residual) and adverse events (AEs) that changed after first drug intake. 
      RESULTS: After the screening, 8 eligible randomized controlled trials with 1316 
      patients were identified. Doxazosin-GITS showed a significantly higher efficacy 
      compared with tamsulosin (IPSS-T P < .001, IPSS-S P < .001, and IPSS-V P < .001). 
      There were no significant differences between the 2 drugs for changes in Qmax 
      (P = .477) or postvoid residual (P = .739). The overall AEs were significantly 
      lower in the doxazosin-GITS group (risk ratio: 0.77; 95% CI: 0.54-1.08; 
      P = .036). However, dizziness (P = .387), headache (P = .745), asthenia 
      (P = .693), postural hypotension (P = .114), and retrograde ejaculation 
      (P = .187) were similar between the 2 groups. CONCLUSIONS: This meta-analysis 
      indicates that doxazosin-GITS has significantly higher efficacy and lower AEs 
      than tamsulosin in patients with lower urinary tract symptoms/benign prostate 
      hyperplasia.
CI  - Copyright (c) 2021 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Guo, Jianming
AU  - Guo J
AUID- ORCID: 0000-0001-8736-8657
AD  - Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.
FAU - Tang, Rong
AU  - Tang R
AD  - Viatris Pharmaceuticals Co., Ltd, Shanghai, China.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Urological Agents)
RN  - G3P28OML5I (Tamsulosin)
RN  - NW1291F1W8 (Doxazosin)
SB  - IM
MH  - Doxazosin/adverse effects/*therapeutic use
MH  - Humans
MH  - Lower Urinary Tract Symptoms/*drug therapy/etiology
MH  - Male
MH  - Prostatic Hyperplasia/*complications
MH  - Tamsulosin/adverse effects/*therapeutic use
MH  - Treatment Outcome
MH  - Urological Agents/adverse effects/*therapeutic use
PMC - PMC8376339
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2021/08/21 06:00
MHDA- 2021/09/01 06:00
PMCR- 2021/08/20
CRDT- 2021/08/20 09:05
PHST- 2021/03/04 00:00 [received]
PHST- 2021/07/30 00:00 [accepted]
PHST- 2021/08/20 09:05 [entrez]
PHST- 2021/08/21 06:00 [pubmed]
PHST- 2021/09/01 06:00 [medline]
PHST- 2021/08/20 00:00 [pmc-release]
AID - 00005792-202108200-00032 [pii]
AID - MD-D-21-01818 [pii]
AID - 10.1097/MD.0000000000026955 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2021 Aug 20;100(33):e26955. doi: 
      10.1097/MD.0000000000026955.